Patient-Centric SC 1 st Strategies in Advanced Drug Development
Monday, July 26th - 12pm (Noon) EDT
|
Sponsored By:
|
|
Biologics are highly complex drugs and many of their characteristics are defined by the manufacturing process. In recent years, several biologics, which were in the past only available for intravenous (IV) use have been co-formulated, developed and approved for subcutaneous (SC) administration. Patient communities, healthcare systems and payors are increasingly seeking optionality and options that reduce the treatment burden associated with visiting the infusion center as required for IV administration.
Halozyme, the developer of the ENHANZE® drug delivery technology, argenx, a global immunology company and a patient with a rare disease, (will provide) will discuss how the technical and developmental advances for a clinical program developing a SC formulation as the initial presentation directly benefits the patient experience. The panel will also discuss strategies for optimizing the clinical development of SC formulations.
Halozyme, the developer of the ENHANZE® drug delivery technology, argenx, a global immunology company and a patient with a rare disease, (will provide) will discuss how the technical and developmental advances for a clinical program developing a SC formulation as the initial presentation directly benefits the patient experience. The panel will also discuss strategies for optimizing the clinical development of SC formulations.
